Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Down 35.9% in August

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 42,034 shares, a decrease of 35.9% from the July 30th total of 65,538 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average trading volume of 28,832 shares, the short-interest ratio is currently 1.5 days.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NEUP. Millennium Management LLC purchased a new stake in shares of Neuphoria Therapeutics in the third quarter valued at $216,000. Geode Capital Management LLC raised its stake in shares of Neuphoria Therapeutics by 33.3% in the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock valued at $67,000 after acquiring an additional 4,325 shares in the last quarter. AdvisorShares Investments LLC lifted its stake in shares of Neuphoria Therapeutics by 129.1% in the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock worth $521,000 after buying an additional 75,631 shares during the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of Neuphoria Therapeutics in the fourth quarter valued at about $43,000. Finally, Persistent Asset Partners Ltd lifted its holdings in shares of Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock worth $52,000 after buying an additional 8,495 shares during the last quarter. 15.90% of the stock is owned by hedge funds and other institutional investors.

Neuphoria Therapeutics Price Performance

Shares of NASDAQ:NEUP opened at $3.75 on Thursday. The stock’s 50 day moving average price is $3.77 and its 200 day moving average price is $4.35. The stock has a market cap of $20.27 million, a price-to-earnings ratio of -0.34 and a beta of 0.75. Neuphoria Therapeutics has a 12 month low of $3.19 and a 12 month high of $21.40.

Wall Street Analysts Forecast Growth

NEUP has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Wall Street Zen raised Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Finally, HC Wainwright downgraded Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $21.00.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.